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Summary: Molecular rapid diagnostic testing (mRDT) in bloodstream infections significantly 
decreased the risk of mortality overall and with stewardship but not without. Time to effective 
therapy, as well as length of stay, were decreased with mRDT. 
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Background: Previous reports on molecular rapid diagnostic testing (mRDT) do not 
consistently demonstrate improved clinical outcomes in bloodstream infections (BSIs). This 
meta-analysis seeks to evaluate the impact of mRDT in improving clinical outcomes in BSIs. 
Methods: We searched PubMed, CINAHL, Web of science, and EMBASE through May 2016 
for BSI studies comparing clinical outcomes by mRDT and conventional microbiology methods. 
Results: Thirty-one studies were included with 5,920 patients. Risk of morality was significantly 
lower with mRDT as compared to conventional microbiology methods (OR 0.66, 95% CI 0.54-
0.80) yielding a NNT of 20. The risk of mortality was slightly lower with mRDT in studies with 
antimicrobial stewardship programs (ASPs) (OR 0.64, 95% CI 0.51-0.79) and non-ASP studies 
failed to demonstrate a significant decrease in risk of mortality (OR 0.72, 95% CI 0.46-1.12). 
Significant decreases in mortality risk were observed with both Gram-positive (OR 0.73, 95% CI 
0.55-0.97) and Gram-negative organisms (OR 0.51, 95% CI 0.33-0.78) but not yeast (OR 0.90, 
95% CI 0.49-1.67). Time to effective therapy decreased by a weighted mean difference of -5.03 
hours (95% CI -8.60 to -1.45) and length of stay decreased by -2.48 days (95% CI -3.90 to -
1.06). 
Conclusions: For BSIs, mRDT was associated with significant decreases in risk of mortality in 
the presence of a ASP, but not in its absence. Additionally, mRDT decreased time to effective 
therapy and length of stay. mRDT should be considered as part of the standard of care in 
patients with BSIs. 
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Background 
Bloodstream infections (BSIs) are associated with significant morbidity, mortality, and increased 
length of stay (LOS) [1,2]. Delayed administration of effective antibiotics increases the risk of 
mortality and therefore correct selection of an antibiotic regimen early in the treatment process 
is paramount [3,4]. Delayed identification of the causative organism and culture susceptibilities 
may often be responsible for delays in optimal antimicrobial therapy. Molecular rapid diagnostic 
testing (mRDT), which includes tests such as polymerase chain reaction (PCR), matrix-assisted 
laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and peptide 
nucleic acid fluorescent in situ hybridization (PNA-FISH), has improved upon conventional 
microbiological methods, reducing time to organism identification, optimizing antimicrobial 
therapy, and subsequently improving clinical outcomes, including mortality [5].   
 
Advancement of RDT is now one of five overarching goals from the National Action Plan for 
Combating Antibiotic-Resistant Bacteria [6]. Additionally, the 2016 Infectious Diseases Society 
of America (IDSA) antimicrobial stewardship program (ASP) guidelines recommend the use of 
rapid diagnostic testing with ASP support and intervention as an addition to conventional 
methods for blood specimens to improve clinical outcomes [7].  Widespread implementation of 
this technology has been limited due to inadequate outcomes data and high costs [8]. A recent 
meta-analysis included evaluations of the clinical benefits of molecular and phenotypic rapid 
diagnostics in BSIs, but was limited by the time frame of the literature included, with the most 
recent study being published in 2012 [9].  Additionally, the impact on LOS was not assessed, 
nor was the effect on mortality according to ASP presence. The objective of this systematic 
review and meta-analysis was to provide a comprehensive and up-to-date assessment of 
mRDT on mortality, time to effective therapy, and LOS, when compared to conventional 
microbiology methods in patients with BSIs. 
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Methods 
Literature Search 
We searched PubMed, CINAHL, Web of Science, and Embase from inception to May 31, 2016 
for BSI studies in English comparing clinical outcomes by mRDT and conventional microbiology 
methods. The search query used was (bacteremia or “bloodstream infection”) AND 
(spectrometry OR "Matrix assisted laser desorption/ionization" OR MALDI-TOF OR microarray 
OR PCR OR "nucleic acid" OR PNA OR molecular OR "polymerase chain reaction") AND 
("length of stay" OR mortality OR morbidity OR diagnosis OR outcome). Two authors (TTT and 
JBM) searched the literature and performed article selection independently. Differences were 
resolved through consensus involving a third author (KWM). A manual search of the included 
articles’ references was conducted to identify additional relevant studies. Unpublished studies 
were included through searching abstracts from IDWeek, Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC), and European Congress of Clinical 
Microbiology and Infectious Diseases (ESCMID) from 2007 to 2015 using the keywords 
bacteremia or bloodstream infection.  
 
Study Selection 
All studies evaluating the differences in clinical outcomes between mRDT, either for organism 
identification and/or resistance mechanism detection, and conventional methods in BSIs were 
eligible for inclusion. mRDT was defined as commercially available molecular tests that are able 
to provide results in 24 hours or less. Studies were included if results were reported for clinical 
outcomes of interest. Studies were excluded if they were non-English studies, evaluated 
infections with mycobacterial, viral, or parasitic organisms, or if mRDT was utilized on negative 
blood cultures or direct blood specimens (e.g. Septifast). 
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Outcomes 
Outcomes evaluated included overall mortality, mortality in studies with ASP, mortality by 
organism, time to effective therapy, and LOS. Mortality was defined as all-cause 30-day or in-
hospital. Organism types were grouped by Gram positive, Gram negative, yeast, or if a 
combination thereof, were termed multiple. Time to effective therapy was defined as the time 
from either blood specimen obtainment or positive test to a therapy with in vitro activity against 
the infecting organism.  LOS was defined as total hospital or from culture (collection or 
positivity) LOS among either survivors or all patients within the study. Studies were classified as 
ASP studies if the authors reported infectious diseases physician or pharmacist review of 
antimicrobial selection based upon culture or mRDT results. 
 
Quality Assessments 
Assessments of quality were made by two authors (TTT and JBM) using the Newcastle-Ottawa 
Scale (NOS) [10] for observation studies and the Risk of Bias (ROB) tool for randomized 
controlled trials (RCT) [11]. NOS evaluates for the selection of patients, comparability of 
patients, and assessment of outcomes. The ROB tool assess whether there is a low, high, or 
unclear level of bias based on five primary domains of bias in RCTs, including selection, 
performance, detection, attrition, and reporting bias [12]. Differences in quality assessment 
between the two authors were resolved through consensus involving a third author (KWM).  
 
Data Extraction and Analysis 
All meta-analyses were performed using Review Manager v.5.3. Mortality outcomes were 
assessed using a random effects model to estimate pooled odds ratios (OR) and 95% 
confidence intervals (CI) with Dersimonian and Laird weights [13]. To express the effect of 
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testing in clinical terms, the number needed to treat (NNT) to prevent one death was calculated. 
The effect of mRDT on time to effective therapy and LOS was evaluated using a random effects 
model and reported as weighted mean difference and 95% CI. Medians and interquartile ranges 
or ranges were converted to means and standard deviations according to Wan et al. [14].  
Publication bias was assessed using funnel plots and Egger’s test. Heterogeneity between 
studies was evaluated with the I2 estimation and Cochran Q test [12]. For heterogeneity testing, 
P < .10 was considered significant as the Q test has low power. Random-effects univariate 
meta-regressions were performed for covariates that had possible effects on an outcome and 
were reported in ≥ 10 studies using the metaphor package in R v.3.2.3. This systematic 
literature review and meta-analysis was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1). 
 
Results 
The literature search resulted in 7,273 studies meeting the keyword criteria (Figure 1). After 
removing duplicates, titles and abstracts were reviewed for 5,426 studies. Studies not related to 
our search were removed yielding 40 studies for full text review. Full-text review identified 5 
articles with data not relevant to our meta-analysis, 3 studies without clinical outcomes, 2 
studies with mRDT in each comparison arm, and 2 studies that evaluated mRDT on blood 
specimens in septic patients without positive cultures. Review of the references of the included 
studies resulted in 4 additional studies being added to the meta-analysis. Data were extracted 
from 31 studies with 5,920 patients as two studies [15,16] contained overlapping data.  
 
Characteristics of the included studies are shown in Table 1. Only 6 studies (19.4%) [17–22] 
were conducted outside of the United States. The majority of studies included (26/31, 83.9%) 
were designed as pre- post-intervention quasi-experimental studies when initiating mRDT. 
While most of the studies reporting study setting were academic medical centers, 2 included 
7 
 
studies (6.5%) [23,24] were from community hospitals. Among studies reporting patient 
population information, adult patients were the most common cohort studied (95.2%, 20/21). 
Gram-positive organisms were the most frequently reported BSI type included, occurring in 17 
studies (54.8%), followed by Gram-negative organisms with 7 studies (22.6%). Multiple 
organism and yeast studies comprised the remainder with 5 (16.1%) and 2 studies (6.5%), 
respectively.  
 
Laboratory practices varied among studies, including mRDT technologies used, frequency of 
testing, and reporting processes. PCR or other microarray technologies were most frequently 
utilized (20/31, 64.5%), followed by PNA-FISH (6/31, 19.4%) and MALDI-TOF (4/31, 12.9%). 
One study (3.2%) utilized both a nanotechnology microarray system and confirmatory MALDI-
TOF [25]. A distinction of MALDI-TOF analysis from direct blood specimen vs overnight solid 
media incubation was reported in 4 of 5 MALDI-TOF studies [15,24,26,35] with a single study 
[26] reporting the latter method.  Of the 19 studies reporting the frequency of laboratory sample 
testing, 5 studies (26.3%) reported real-time testing, 10 studies (52.6%) batch testing between 1 
to 4 times daily, and 3 studies (15.8%) reported real-time testing during limited time frames (e.g. 
7am-7pm). Among the 5 studies performing 24x7 real-time testing, mRDT result notifications 
were reported as being performed in real time for two studies [27, 33] while another study [40] 
only notified of the results and in real time if resistance genes were detected. Finally, notification 
methods also varied between studies when reported, with the majority of the reporting studies 
(17/29, 58.6%) reporting directly to the primary team or physician, while 3 studies (10.3%) 
reported to the result to nurses.  
 
ASP activities varied by study. The presence of an ASP facilitating mRDT represented the 
majority of the data (20/31, 64.5%). In the 14 studies reporting ASP notification processes, only 
half were 24x7 real-time. The remainder had set response hours (e.g., 8a-5p M-F) or once daily 
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review of results. Two studies [23,27], which were both quasi-experimental, explicitly stated 
whether the ASP was present in both periods with one [23] of the two having an ASP in the post 
period only.  
 
Clinical outcomes in BSIs generally favored mRDT over conventional microbiology (Figures 2 
and 3). Among 26 studies [5,15,17–20,23,24,26,28–44], the odds of mortality were significantly 
lower with mRDT (OR 0.66, 95% CI 0.54 to 0.80) yielding a NNT of 20. Stratification revealed 
that the odds of mortality were significantly lower for BSIs using mRDT with ASP (OR 0.64, 95% 
CI 0.51 to 0.79), but failed to achieve significance without ASP support (OR 0.72, 95% CI 0.46 
to 1.12). Similar results were observed when a sensitivity analysis was performed using studies 
[17,20,26,29,36,40,43] which controlled for confounding (Supplementary Figure 1). When 
evaluating mortality by organism type (Figure 3), there was no significant difference in the odds 
of mortality among yeast isolates (OR 0.90, 95% CI 0.49 to 1.67). In contrast, the odds of 
mortality were reduced with mRDT among Gram-negative (OR 0.51, 95% CI 0.33 to 0.78), 
Gram-positive (OR 0.73, 95% CI 0.55 to 0.97), and multiple organism testing (OR 0.58, 95% CI 
0.32 to 1.04). Mortality in multiple organism testing had significant heterogeneity (Cochran’s Q P 
= .07, I2 = 53%) due to a study [17] which used both mRDT and rapid susceptibility testing. 
Exclusion of that study yielded a 51% decreased odds of mortality in multiple organism testing 
(OR 0.49, 95% CI 0.33 to 0.71, Cochran’s Q P = .56, I2 = 0%). Sensitivity analysis using studies 
[17,20,26,29,36,40,43] controlling for confounding achieved non-significant reductions in risk of 
mortality by each organism group (Supplementary Figure 2). Meta-regressions of covariates by 
the presence of an ASP (P = .56), organism type (P = .42), real-time ASP (P = .82), or real-time 
mRDT (P = .34) as possible moderators for mortality were not significant. 
 
Among 9 studies [20–22,25,26,33,34,37,44], time to effective therapy (Supplementary Figure 3) 
was significantly decreased by a weighted mean difference of -5.03 hours (95% CI -8.60 to -
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1.45) with mRDT versus conventional microbiology. Time to effective therapy had significant 
heterogeneity (Cochran’s Q P = .0002, I2 = 74%) due to a study [33] which was limited to 
vancomycin resistant enterococci (VRE). Exclusion of that study yielded time to effective 
therapy with a decreased weighted mean difference of -1.89 hours (95% CI -2.43 to -1.36, 
Cochran’s Q P = .48, I2 = 0%). Evaluation of that study [33] and VRE subgroup data from 2 
studies [25,36] yielded a time to effective therapy weighted mean difference of -26.65 h (95% CI 
-35.43 to -17.88, Cochran’s Q P = .66, I2 = 0%). Finally, LOS (Supplementary Figure 4) was 
significantly shorter with mRDT by -2.48 days (95% CI -3.90 to -1.06) and similar results were 
observed among subgroups by total hospital LOS and from culture LOS. Sensitivity analysis 
was performed using the only two studies [17,36] that controlled for confounding and reflected a 
decreased LOS by a WMD of -8.08 days (-20.59 to 4.44, Cochran’s Q P < .0001, I2 = 95%). 
 
Analysis of the potential for publication bias with funnel plots (Supplementary Figures 5-7) 
suggested no evidence of publication bias for the analyses presented in Figures 2-3 and 
Supplementary Figure 3. Similarly, Egger’s regression testing reflected an absence of 
publication bias for the analyses presented in Figures 2, 3, and Supplementary Figure 3 (P = 
.98, P = .98, P = .07, respectively). However, Egger’s regression testing suggested possible 
publication bias with the LOS analysis (Supplementary Figure 4; P = .01).  
 
Discussion 
In this systematic review and meta-analysis of 31 studies and 5,920 BSI patients, mRDT was 
associated with a decreased risk of mortality and LOS, as well as improved time to effective 
therapy compared to conventional microbiological methods. The extent of adoption of mRDT for 
BSIs among acute care facilities in the United States is unknown, although use of rapid 
diagnostic tests for identification of drug resistant organisms and improving stewardship has 
been called for by the National Action Plan for Combating Antibiotic-Resistant Bacteria [6]. 
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While a number of observational studies have supported the use of mRDT with ASPs for 
improving clinical outcomes, a recent randomized control trial has suggested these technologies 
have a limited impact [45]. However, it should be noted that the aforementioned study’s 
definition of standard blood culture processing included MALDI-TOF, and therefore included 
mRDT in both comparator groups. 
 
Clinical implications with the use of rapid diagnostics in BSIs has been evaluated in one meta-
analysis [9]. While the previous meta-analysis evaluated the use of RDT with communication of 
results to providers, the role of ASP was not explored. Additionally, the meta-analysis was 
limited by its literature review time frame and did not focus solely on molecular technologies. In 
the current meta-analysis with 16 additional studies, we explored the relationship between 
mRDT and ASP specifically. We found that mortality decreased significantly with mRDT in the 
presence of ASP but not its absence. Thus, we believe our results support the IDSA ASP 
guideline recommendation to utilize rapid diagnostics with ASP facilitation in BSIs [7]. Moreover, 
our analysis approximates that mRDT would only need to be used in 20 patients with BSI in 
order to prevent one death within 30 days, which further supports mRDT as the standard of care 
in BSIs.  
 
Compared to conventional microbiologic methods, mRDT was associated with significantly 
decreased risk of mortality among gram-negative organisms, gram-positive organisms, and 
multiple infection type studies, while yeast studies did not achieve significant mortality 
reductions. However, among studies [17,20,26,29,36,40,43] controlling for confounding, non-
statistically significant reductions in risk of mortality were observed by organism groups. Failure 
to demonstrate the benefit of mRDT in yeast BSIs on risk of mortality or among studies in the 
sensitivity analysis may be due to the limited number of studies and corresponding sample 
sizes. 
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Detecting true mortality benefits may be difficult in pre-post studies that have not controlled for 
confounding. Therefore, the use of an outcome more directly related to mRDT, such as time to 
effective therapy, may be a better indicator of mRDT benefits. Despite few studies reported time 
to effective therapy, we did observe a significant decrease in time to effective therapy. However, 
the distribution of time to effective therapy varied both within and between studies. The 
importance of time to effective therapy has been recently demonstrated in a study of VRE 
bacteremia which reported a 3-fold increase in 30-day mortality in the absence of effective 
therapy in the first 48h of BSI, and speculated that rapid diagnostics may be beneficial in 
reducing time to effective therapy in the setting of VRE [3]. Our results suggest the particular 
utility of mRDT in VRE BSIs, improving time to effective therapy by over 24 hours. Furthermore, 
the mean time to effective therapy for all three VRE studies included in our analysis ranged from 
43.7 hours to 50.2. As such, we believe mRDT may have profound benefits in patients with VRE 
bacteremia, and may help minimize risk of mortality. 
 
Finally, significant decreases in LOS were observed. While we did not evaluate costs, the 
observed decreases in LOS have significant implications based on savings of cost per day for 
hospitalization. A study evaluating the economic impact of mRDT in BSI demonstrated an 
estimated $30,000 cost savings per 100 patients after accounting for mRDT costs [36]. 
However, the generalizability of decreased LOS reported  are likely limited to large hospitals 
and medical centers as only two of the included studies were community hospitals. Additionally, 
LOS did not achieve significant reductions among the two studies [17,36] which controlled for 
confounding, although the significant heterogeneity in this analysis and small sample limit 
inference of these results. 
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There are several limitations to this systematic review and meta-analysis. For LOS, our analysis 
suggested possible publication bias. However, this may be related to the small number of 
studies reporting this outcome. While the generalizability of our findings for clinical outcomes 
may be limited to academic medical centers, it should be noted that two community hospital 
studies were included [23,24]. In one of the community hospital studies, while an ASP was 
present, non-ID trained pharmacists responded to the BSIs [24]. Future studies from the 
community hospital setting elucidating outcomes would help to clarify best practices in this area. 
Guidance for recording and reporting these outcomes when using RDT in BSIs has been 
described and should be utilized by researchers in the future [9]. In addition, we treated all 
interventions as equal with regards to technology type due to variability in laboratory practices 
such as batching of assays or performing MALDI-TOF either directly from blood culture bottles 
containing nutritional broth or from solid agar incubated overnight. Notification methods for 
mRDT results also varied which could have implications on clinical outcomes. While future 
evaluations may consider these variations and their relationship to clinical outcomes, our 
analysis supports mRDT as a group improves outcomes in BSIs. Additionally, we believe the 
implementation of mRDT should include an action plan to ensure correct interpretation, real-
time reporting, and guidance on optimal therapy. Having 24x7 testing, with immediate 
notifications to the provider along with direction from an ASP team, will facilitate the initiation, 
escalation, or de-escalation of therapy in a meaningful timeframe.  
 
Conclusion 
mRDT was associated with significant decreases in morality in the presence of an ASP, but not 
in its absence. Significant decreases in risk of mortality were also seen for gram-positive 
organisms, gram-negative organisms, and multiple organism infection studies. Additionally, 
mRDT was associated with decreased time to effective therapy and LOS. The greatest benefit 
of mRDT for improving time to effective therapy may be for BSIs caused by resistant organisms, 
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particularly VRE. Additional studies in community hospitals are needed, as are additional 
studies elucidating the benefits of various microbiologic technologies in combination with ASP to 
define best practices. Based on the clinical outcomes, mRDT should be considered as part of 
the standard of care in patients with BSIs. 
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Figure 1: Flow diagram. 
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Figure 2: Mortality with mRDT vs conventional testing in BSI. 
 
	  
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; ASP, antimicrobial 
stewardship program; M-H, Mantel-Haenszel method; CI, confidence interval.	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Figure 3: Mortality with mRDT vs conventional testing by organism type in BSI.	  
	  
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; M-H, Mantel-Haenszel 
method; CI, confidence interval.
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Table 1. Characteristics of Included Studies of Included in Systematic Review and Meta-analysis 
Author 
Year 
Study 
Design Setting 
Patient 
Population 
Sample Size, 
mRDT/Control, 
No. of Patients 
BSI Type Laboratory Tests 
mRDT 
Testing & 
Notification 
Recipient 
ASP 
Presence 
ASP 
Notification 
Process 
NOS 
Score 
Bauer [27] 
2010 
Quasi-
experimental 
1150-bed 
tertiary care 
facility 
Adult 82/74 S. aureus Conventional vs PCR 
24x7; 
Physician Yes 
Real-time 
M-F 8a-5p 9 
Beuving [17] 
2015 RCT 
750-bed 
hospital Adult 129/121 Multiple 
Conventional 
vs PCR 
NR; 
Physician No NA NA 
Bias [28] 
2015 
Quasi-
experimental NR Adult 49/65 
Gram-negative 
organisms 
Conventional 
vs BC-GN 
NR; 
Physician & 
ASP 
Yes NR 7 
Box [23] 
2015 
Quasi-
experimental 
5 
Community 
hospitals 
Adult 64/103 Gram-positive organisms 
Conventional 
vs BC-GP 
7a-7p; 
Nurse Yes 
Real-time 
7a-7p 7 
Cattoir [22] 
2011 
Quasi-
experimental 
900-bed 
teaching 
hospital 
Adult 49/48 Staphylococcus spp. 
Conventional 
vs PCR 
NR; 
Physician No NA 9 
Felsenstein [41] 
2016 
Quasi-
experimental 
Children’s 
hospital Pediatric 219/221 
Gram-positive 
organisms 
Conventional 
vs BC-GP 
24x7 testing 
but not real-
time; 
Physician 
No NA 8 
Forrest [30] 
2006 
Quasi-
experimental 
Medical  
center NR 72/76 Yeast 
Conventional 
vs PNA-
FISH 
1x/day; 
Team & 
ASP 
Yes Real-time 7 
Forrest [29] 
2006 Case-control 
740-bed  
medical  
center 
NR 119/84 CoNS 
Conventional 
vs PNA-
FISH 
1x/day; 
Team & 
ASP 
Yes Real-time 9 
Forrest [31] 
2008 
Quasi-
experimental 
600-bed 
teaching 
hospital 
Adult 95/129 Enterococcus spp. 
Conventional 
vs PNA-
FISH 
2x/day; 
Physician & 
ASP 
Yes Real-time 7 
Frye [42] 
2012 
Quasi-
experimental 
Two 500-
bed medical 
centers 
Adult 110/134 Staphylococcus spp. 
Conventional 
vs PCR 
2x/day M-F, 
1x/day SS; 
MRSA 
results to 
floor 
No NA 9 
Heil [32] 
2012 
Quasi-
experimental NR Adult 21/61  Yeast 
Conventional 
vs PNA-
FISH 
7a-9:30p; 
Physician & 
PharmD 
Yes Real-time 7 
Holtzman [46] 
2011 
Quasi-
experimental 
Medical 
center Adult 99/100 CoNS 
Conventional 
vs PNA-
FISH 
1x/day; EHR 
only No NA 9  
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 Table 1 continued. 
Author 
Year 
Study 
Design Setting 
Patient 
Population 
Sample Size, 
mRDT/Control, 
No. of Patients 
BSI Type Laboratory Tests 
mRDT 
Testing & 
Notification 
Recipient 
ASP 
Presence 
ASP 
Notification 
Process 
NOS 
Score 
Huang [26] 
2013 
Quasi-
experimental 
Health 
system Adult  245/256 Multiple 
Conventional 
vs MALDI-
TOF 
NR; 
Ordering 
clinician & 
ASP 
Yes 6a-11:30p 9 
Lockwood [24] 
2016 
Quasi-
experimental 
2 
community 
hospitals 
Adult 241/149 Gram-negative organisms 
Conventional 
vs MALDI-
TOF 
NR; Nurse 
& ASP Yes Real-time 7 
Ly [43] 
2008 RCT 
907-bed 
tertiary 
care center 
Adult  101/101 Staphylococcus spp. 
Conventional 
vs PNA-
FISH 
2x/day; 
Treating 
clinician 
No NA NA 
Macvane [34]  
2015 
Quasi-
experimental NR Adult 63/50 
Gram-negative 
organisms 
Conventional 
vs PCR NR; NR Yes NR 7 
Macvane [33]  
2016 
Quasi-
experimental 
709-bed 
academic 
center 
Adult 23/45 Enterococcus spp. 
Conventional 
vs PCR 
24x7; 
Nurse and 
PharmD 
Yes Real-time 8a-5p M-F 7 
Maslonka [44] 
2014 
Case-
Control NR NR 55/55 Multiple 
Conventional 
vs PCR NR; NR No NA 7 
Na [21] 
2016 
Quasi-
experimental 
Academic 
hospital NR 97/94 
Staphylococcus 
spp. 
Conventional 
vs PCR 
1x/day M-
Sat; EHR 
only 
No NA 7 
Nagel [35] 
2014 
Quasi-
experimental 
Health 
system Adult 117/129 CoNS 
Conventional 
vs MALDI-
TOF 
NR; 
Physician 
& ASP 
Yes 6a-11:30p 7 
Neuberger [20] 
2008 
Quasi-
experimental 
Tertiary 
care 
medical 
center 
NR 42/42 Klebsiella pneumoniae 
Conventional 
vs PCR 
11p-11a 
M-F; 
Physician 
No NA 9 
Nguyen [47] 
2010 
Quasi-
experimental 
Academic 
hospital Adult  94/65 
Staphylococcus 
spp. 
Conventional 
vs PCR 
NR; EHR 
only No NA 9 
Pardo [36] 
2016 Case-control 
939-bed 
academic 
medical 
center 
Adult  84/252 Multiple Conventional vs PCR 
1x/day; 
ASP Yes NR 9 
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Table 1 continued. 
Author 
Year 
Study 
Design Setting 
Patient 
Population 
Sample Size, 
mRDT/Control, 
No. of Patients 
BSI Type Laboratory Tests 
mRDT 
Testing & 
Notification 
Recipient 
ASP 
Presence 
ASP 
Notification 
Process 
NOS 
Score 
Perez [15] 
2013 
Quasi-
experimental 
1000-bed 
quaternary 
care 
academic 
hospital 
Adult 107/112 Gram-negative organisms 
Conventional 
vs MALDI-
TOF 
3-4x/day; 
ASP Yes Real-time 9 
Revolinksi [37] 
2015 
Quasi-
experimental NR Adult 95/133 
Gram-positive 
organisms 
Conventional 
vs BC-GP 
NR; 
Provider & 
PharmD 
Yes NR 7 
Roshdy [25] 
2015 
Quasi-
experimental 
Academic 
medical 
center 
NR 74/65 
Streptococcus / 
Enterococcus 
spp. 
Conventional 
vs BC-GP + 
MALDI-TOF 
NR; 
PharmD Yes NR 7 
Sango [38] 
2013 
Quasi-
experimental 
695-bed 
academic 
medical 
center 
NR 28/46 Enterococcus spp. 
Conventional 
vs BC-GP 24x7; ASP Yes 
M-F 7:30a-
5p 7 
Sothoron [39] 
2015 
Quasi-
experimental NR Adult 67/59 
Gram-negative 
organisms 
Conventional 
vs BC-GN 24x7; ASP Yes Real-time 7 
Suzuki [19] 
2015 
Quasi-
experimental 
413-bed 
tertiary 
medical 
center 
NR 88/147 Multiple 
Conventional 
vs BC-
GP/GN 
NR; 
Hospital 
physician 
and ID 
physician 
Yes NR 7 
Walker [40] 
2016 
Quasi-
experimental 
401-bed 
tertiary 
care & 60-
bed 
cancer 
hospitals 
NR 97/98 Gram-negative organisms 
Conventional 
vs BC-GN 
24x7; 
Physician 
if resistant 
organism 
Yes Daily 9 
Wang [18] 
2013 
Quasi-
experimental 
1200-bed 
tertiary 
care 
hospital 
NR 48/38 Staphylococcus spp. 
Conventional 
vs PCR 
1x/day; 
Physician No NA 7 
Note. MALDI-TOF, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight; BC-GP, blood culture gram positive nanotechnology microarray system; BC-GN 
blood culture gram negative nanotechnology microarray system; NR, not reported; NA, not applicable; NOS, Newcastle-Ottawa Scale; ROB, Risk of Bias; AST, 
antibiotic susceptibility testing; EHR, electronic health record. 
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Appendix 
Supplementary Table 1: PRISMA Checklist 
Section/topic  # Checklist item  Reported on 
page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  3 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  - 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  4 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  4-5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  4-5 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  5 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  5 
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Supplementary Table 1: PRISMA Checklist (Cont.) 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  5-6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
6, 
Figure 1 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
6-7, 
Table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Supplementary Table 
1 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Figures 2-3, 
Supplementary  
Figures 1-4 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
7-8, 
Figures 2-3, 
Supplementary 
Figures 1-4 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  8, Supplementary 
Figures 5-7 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
7-8, 
Figures 2-3, 
Supplementary 
Figures 1-2,4 
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  8-10 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  10-11 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  11 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role 
of funders for the systematic review.  NA 
 
Supplementary Table 2: Newcastle-Ottawa Scale Quality Assessment Scores 
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Author Selection (max 4 stars) 
Comparability 
(max 2 stars) 
Outcome 
(max 3 stars) Total Score 
Bauer [27] **** ** *** 9 
Bias [28] ****  *** 7 
Box [23] ****  *** 7 
Cattoir [22] **** ** *** 9 
Felsenstein [41] **** * *** 8 
Forrest [30] ****  *** 7 
Forrest [29] **** ** *** 9 
Forrest [31] ****  *** 7 
Frye [42] **** ** *** 9 
Heil [32] ****  *** 7 
Holtzman [46] **** ** *** 9 
Huang [26] **** ** *** 9 
Lockwood [24] ****  *** 7 
Macvane [34] ****  *** 7 
Macvane [33] ****  *** 7 
Maslonka [44] ****  *** 7 
Na [21] ****  *** 7 
Nagel [35] ****  *** 7 
Neuberger [20] **** ** *** 9 
Nguyen [47] **** ** *** 9 
Pardo [36] **** ** *** 9 
Perez [15] **** ** *** 9 
Revolinski [37] ****  *** 7 
Roshdy [25] ****  *** 7 
Sango [38] ****  *** 7 
Sothoron [39] ****  *** 7 
Suzuki [19] ****  *** 7 
Walker [40] **** ** *** 9 
Wang [18] ****  *** 7 
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Supplementary Table 3. Risk of Bias Quality Assessments 
Author 
 
Random sequence 
generation 
Allocation 
concealment 
Blinding of participants 
and personnel 
Blinding of outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Other 
bias 
Beuving [17] Low Low High High Low Low Unclear 
Ly [43] High High High High Low Low High 
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Supplementary Figure 1. Mortality with mRDT vs conventional testing in BSI among studies controlling for confounding. 
 
Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; ASP, antimicrobial stewardship program; M-H, 
Mantel-Haenszel method; CI, confidence interval. 
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Supplementary Figure 2. Mortality with mRDT vs conventional testing by organism type in BSI among studies controlling for 
confounding. 
 
Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; M-H, Mantel-Haenszel method; CI, confidence 
interval. 
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Supplementary Figure 3. Time to effective therapy with mRDT vs conventional testing in BSI. 
 
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; IV, Inverse variance 
method; CI, confidence interval.  
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Supplementary Figure 4. Length of stay with mRDT vs conventional testing in BSI. 
 
*Conference abstract. Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; LOS, length of stay; IV, 
Inverse variance method; CI, confidence interval. 
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Supplementary Figure 5. Funnel plot of included studies for mortality of mRDT vs conventional testing in BSI. 
 
Abbreviations: mRDT, molecular rapid diagnostic testing; ASP, antimicrobial stewardship program; BSI, bloodstream infection; SE, 
standard error; OR, odds ratio. 
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Supplementary Figure 6. Funnel plot of included studies for time to appropriate therapy of mRDT vs conventional testing in BSI. 
 
Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; SE, standard error; MD, mean difference. 
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Supplementary Figure 7. Funnel plot of included studies for length of stay of mRDT vs conventional testing in BSI. 
 
Abbreviations: mRDT, molecular rapid diagnostic testing; BSI, bloodstream infection; SE, standard error; MD, mean difference. 
 
